Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005 socioeconomic disparity and geographic variation in a large population-based cohort

Cancer

Volumn 116, Issue 14, 2010, Pages 3505-3512

  Guadagnolo, B Ashleigh ^a   Liu, Chih Chin ^b   Cormier, Janice N ^a   Du, Xianglin L ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Head and neck cancer; Intensity modulated radiotherapy; Socioeconomic disparities; Technology diffusion

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; COHORT ANALYSIS; DEMOGRAPHY; EVALUATION; FEMALE; GEOGRAPHIC DISTRIBUTION; HEAD AND NECK CANCER; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE UTILIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; SOCIAL STATUS; SOCIOECONOMICS; TREND STUDY; UNITED STATES;

AGED; AGED, 80 AND OVER; FEMALE; HEAD AND NECK NEOPLASMS; HEALTHCARE DISPARITIES; HUMANS; MALE; RADIOTHERAPY, INTENSITY-MODULATED; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 77954929041     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25205     Document Type: Article

References (45)

1. American Cancer Society. Cancer facts & figures 2009. Available at: http://www.cancer.org/downloads/STT/500809 web.pdf Accessed on July 3, 2009.
2. Sidransky D, Schantz SP, Harrison LB, Forastiere A, Sessions RB, Miller SD. Cancer of the head and neck. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Vol1. Philadelphia: Lippincott Williams & Wilkins; 2001:789-916.
3. Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck. 2004;26:796-807. (Pubitemid 39159303)
4. Chambers MS, Rosenthal DI, Weber RS. Radiation-induced xerostomia. Head Neck. 2007;29:58-63.
5. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck. 2001;23:389-398.
6. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695-704.
7. Oh HK, Chambers MS, Martin JW, Lim HJ, Park HJ. Osteoradionecrosis of the mandible: treatment outcomes and factors influencing the progress of osteoradionecrosis. J Oral Maxillofac Surg. 2009;67:1378-1386.
8. Puri DR, Chou W, Lee N. Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results. Am J Clin Oncol. 2005;28: 415-423.
9. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873-4879.
10. Eisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg. 2003;27:832-837.
11. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45:577-587.
12. Studer G, Studer SP, Zwahlen RA, et al. Osteoradionecrosis of the mandible: minimized risk profile following intensitymodulated radiation therapy (IMRT). Strahlenther Onkol. 2006;182:283-288.
13. Ben-David MA, Diamante M, Radawski JD, et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys. 2007;68:396-402.
14. Grant W III, Woo SY. Clinical and financial issues for intensity-modulated radiation therapy delivery. Semin Radiat Oncol. 1999;9:99-107.
15. Klein EE, Tepper J, Sontag M, Franklin M, Ling C, Kubo D. Technology assessment of multileaf collimation: a North American users survey. Int J Radiat Oncol Biol Phys. 1999; 44:705-710.
16. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol. 2008;9:367-375.
17. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer. 2005;104: 1296-1303.
18. National Cancer Institute. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/index.html Accessed on May 26, 2009.
19. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
20. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl):IV-3-IV-18.
21. Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results. J Clin Epidemiol. 1999;52:463-470.
22. Smith GL, Smith BD, Buchholz TA, et al. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol. 2008;26:5119-125.
23. U.S. Public Health Services. International Classification of Diseases-9th Revision. Clinical Modification. 5th ed. Los Angeles, CA: Practice Management Information Corporation; 1996.
24. American Medical Association. Physicians' Current Procedural Terminology-CPT 2000. Chicago, IL: American Medical Association; 2000.
25. Health Care Financing Administration. HCFA Common Procedure Coding System: National Level II Medicare Codes. Los Angeles, CA: Practice Management Corporation; 2000.
26. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:1455-1461. (Pubitemid 32202553)
27. Du XL, Key CR, Dickie L, Darling R, Geraci JM, Zhang D. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care. 2006;44:124-131.
28. National Cancer Institute. SEER-Medicare: Calculation of Comorbidity Weights. Available at: http://healthservices.cancer. gov/seermedicare/program/ comorbidity.html. Accessed on June 8, 2009.
29. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
30. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373-383.
32. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079; discussion 1081-1090.
33. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001;49:907-916.
34. Chao KS, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001;61:275-280.
35. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:981-991.
36. Chen AM, Daly ME, Bucci MK, et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys. 2007;69:141-147.
37. Lee NY, de Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:966-974.
38. David G, Helmchen LA, Henderson RA. Does advanced medical technology encourage hospitalist use and their direct employment by hospitals? Health Econ. 2009;18:237-247.
39. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138:273-287.
40. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med. 2003;138:288-298.
41. Baicker K, Chandra A. Medicare spending, the physician workforce, and beneficiaries' quality of care. Health Aff (Millwood). 2004;(suppl) Web Exclusives:W184-W197.
42. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol. 2008; 26:3937-2942.
43. Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer. 2009;115:2999-3008.
44. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2006;17:5-19. (Pubitemid 43033834)
45. Ayanian JZ, Guadagnoli E. Variations in breast cancer treatment by patient and provider characteristics. Breast Cancer Res Treat. 1996;40:65-74. (Pubitemid 26283491)